Ignite Creation Date:
2025-12-25 @ 2:05 AM
Ignite Modification Date:
2025-12-26 @ 5:03 PM
Study NCT ID:
NCT05604560
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-07-23
First Post:
2022-10-28
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
Sponsor:
Lei Zheng
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11-08
Start Date Type:
ACTUAL
Primary Completion Date:
2026-09
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-09
Completion Date Type:
ESTIMATED
First Submit Date:
2022-10-28
First Submit QC Date:
None
Study First Post Date:
2022-11-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-18
Last Update Post Date:
2025-07-23
Last Update Post Date Type:
ACTUAL